Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With Acquisition of Yellow Jersey Therapeutics
July 12, 2024
July 12, 2024
NEW BRUNSWICK, New Jersey, July 12 -- Johnson and Johnson issued the following news release on July 11, 2024:
Johnson & Johnson1 (NYSE: JNJ) announced today that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody, in an all-cash transaction of approximately $1.25 billion, as announced on May 28, 2024.
NM26, which i . . .
Johnson & Johnson1 (NYSE: JNJ) announced today that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody, in an all-cash transaction of approximately $1.25 billion, as announced on May 28, 2024.
NM26, which i . . .